Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Full description

Bibliographic Details
Published in:Scientific Reports
Main Author: Lee H.-C.; Hamzah H.; Leong M.P.-Y.; Md Yusof H.; Habib O.; Zainal Abidin S.; Seth E.A.; Lim S.-M.; Vidyadaran S.; Mohd Moklas M.A.; Abdullah M.A.; Nordin N.; Hassan Z.; Cheah P.-S.; Ling K.-H.
Format: Article
Language:English
Published: Nature Research 2021
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101446415&doi=10.1038%2fs41598-021-83222-z&partnerID=40&md5=bd59ec493f7c72b6d7626540688eb66f

Internet

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101446415&doi=10.1038%2fs41598-021-83222-z&partnerID=40&md5=bd59ec493f7c72b6d7626540688eb66f

Similar Items